Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(2 sites)

United States

MD Anderson Cancer Center, Houston, Texas

China

Peking University People's Hospital, Beijing, Beijing Municipality